A Phase II/III trial of Somaxon Pharmaceuticals' nalmefene for the treatment of pathological gambling failed to demonstrate a statistically significant difference compared to placebo. The trial evaluated 20 mg and 40 mg of oral nalmefene hydrochloride. Both doses missed the secondary endpoints as well. Ken Cohen, Somaxon's President and CEO, noted, "The results of this clinical trial for nalmefene are disappointing. We will now perform a careful analysis of all of our nalmefene data and our assumptions underlying that program to determine what the next steps should be." Earlier this year Somaxon touted Phase II data for oral nalmefene hydrochloride for smoking cessation.
- check out this press release on the study results
Related Article:
BioTie drug helps blunt thrill of gambling. Report
Somaxon touts mid-stage data on smoking cessation. Report